ContaminantDB: Bromazepam

Identification Taxonomy Biological Properties Physical Properties Toxicity Profile Spectra Concentrations Links References Targets (21)XML

Record Information

Version

1.0

Creation Date

2009-07-21 20:28:51 UTC

Update Date

2026-05-14 17:08:57 UTC

Accession Number

CHEM002396

Identification

Common Name

Bromazepam

Class

Small Molecule

Description

Bromazepam is only found in individuals that have used or taken this drug. It is one of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.Bromazepam binds to the GABA receptor GABA_A, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.

Contaminant Sources

HMDB Contaminants - Urine
STOFF IDENT Compounds
Suspected Compounds
T3DB toxins

Contaminant Type

Amide
Amine
Anti-Anxiety Agent
Benzodiazepine
Bromide Compound
Drug
GABA Modulator
Human Neurotoxin
Hypnotic and Sedative
Metabolite
Organic Compound
Organobromide
Synthetic Compound

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
Lectopam	Kegg
7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiaxepin-2(1H)-one	HMDB
7-Bromo-5-(2-pyridyl)-3H-1,4-benzodiazepin-2(1H)-one	HMDB
1a Brand OF bromazepam	HMDB
Bromazepam lichtenstein brand	HMDB
Bromazepam beta	HMDB
Heumann brand OF bromazepam	HMDB
Lexatin	HMDB
Betapharm brand OF bromazepam	HMDB
Apo-bromazepam	HMDB
Apotex brand OF bromazepam	HMDB
Bromaz 1a pharma	HMDB
Hexal brand OF bromazepam	HMDB
CT-Arzneimittel brand OF bromazepam	HMDB
Durazanil	HMDB
Aliud brand OF bromazepam	HMDB
Apo bromazepam	HMDB
Bromazepam heumann	HMDB
Bromazepam ratiopharm	HMDB
Bromazepam-neuraxpharm	HMDB
Bromazepam-ratiopharm	HMDB
Gen-bromazepam	HMDB
Lexomil	HMDB
Lexotan	HMDB
Roche brand OF bromazepam	HMDB
Neuraxpharm brand OF bromazepam	HMDB
Ratiopharm brand OF bromazepam	HMDB
Anxyrex	HMDB
BromaLich	HMDB
Bromazanil	HMDB
Bromazepam al	HMDB
Bromazepam roche brand	HMDB
Gen bromazepam	HMDB
Genpharm brand OF bromazepam	HMDB
Irex brand OF bromazepam	HMDB
Lexotanil	HMDB
Lichtenstein brand OF bromazepam	HMDB
Merck dura brand OF bromazepam	HMDB
Bromazep von CT	HMDB
CT Arzneimittel brand OF bromazepam	HMDB
Beta, Bromazepam	HMDB
Bromazepam neuraxpharm	HMDB
Von CT, bromazep	HMDB

Chemical Formula

C₁₄H₁₀BrN₃O

Average Molecular Mass

316.153 g/mol

Monoisotopic Mass

315.001 g/mol

CAS Registry Number

1812-30-2

IUPAC Name

7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

Traditional Name

bromazepam

SMILES

BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1

InChI Identifier

InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

InChI Key

VMIYHDSEFNYJSL-UHFFFAOYSA-N

Chemical Taxonomy

Description

belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Benzodiazepines

Sub Class

1,4-benzodiazepines

Direct Parent

1,4-benzodiazepines

Alternative Parents

Substituents

1,4-benzodiazepine
Alpha-amino acid or derivatives
Aryl bromide
Aryl halide
Pyridine
Benzenoid
Heteroaromatic compound
Carboxamide group
Ketimine
Lactam
Secondary carboxylic acid amide
Carboxylic acid derivative
Azacycle
Organic 1,3-dipolar compound
Propargyl-type 1,3-dipolar organic compound
Organobromide
Organohalogen compound
Hydrocarbon derivative
Imine
Organic nitrogen compound
Organic oxide
Carbonyl group
Organonitrogen compound
Organooxygen compound
Organic oxygen compound
Organopnictogen compound
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Pathways

Not Available

Applications

Not Available

Biological Roles

Not Available

Chemical Roles

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	Not Available
Boiling Point	Not Available
Solubility	3.99e-02 g/L

Predicted Properties

Property	Value	Source
Water Solubility	0.04 g/L	ALOGPS
logP	2.09	ALOGPS
logP	2.54	ChemAxon
logS	-3.9	ALOGPS
pKa (Strongest Acidic)	12.24	ChemAxon
pKa (Strongest Basic)	2.68	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	54.35 Å²	ChemAxon
Rotatable Bond Count	1	ChemAxon
Refractivity	76.99 m³·mol⁻¹	ChemAxon
Polarizability	28.11 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	View
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	splash10-000i-0091000000-cf3c3fba2d2e801551b1	Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	Not Available	Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive	Not Available	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0049000000-67c4bd48b889caf68ca3	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-000i-0090000000-8d6819f4db99e73f4dbe	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-002r-6090000000-f5e0ef1096bea72d5c89	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9010000000-19864d6c0a50c513bb18	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9000000000-59557fda51a0ea2c63d7	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9000000000-6b0acd4d149e1fb20f9a	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9000000000-6b0acd4d149e1fb20f9a	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9000000000-6b0acd4d149e1fb20f9a	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-004i-9000000000-6b0acd4d149e1fb20f9a	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-014i-0379000000-14ceeb34a706f6a12f41	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-014i-0009000000-09662342e908d558048e	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-014i-0029000000-4b93291583996cb3cbda	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-05o0-0492000000-035f589c482b481c5152	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-053r-1890000000-1997ad0374625359f483	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-053r-1960000000-4f105348e7e7804313ce	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-053r-1930000000-b0f688a41f88a133b74b	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0f89-1910000000-c0dd1d47a44a292c87b6	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0fb9-2900000000-706d4c35cde468a8387d	Spectrum
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-004i-6900000000-85795e315602b7e61a6b	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	splash10-014i-0019000000-9838285fc2c3cd651ac2	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	splash10-014r-0096000000-280bb1a170e2f078b4e0	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	splash10-000i-2090000000-b45001feb54839adf307	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	splash10-03di-0009000000-f5383e2ca907102396d1	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	splash10-03di-0029000000-68359119cecb7b2899e1	Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	splash10-001i-2191000000-ee5f9b155d34898671dc	Spectrum
MS	Mass Spectrum (Electron Ionization)	splash10-00n0-9463000000-abe7fdab778f08fe18c4	Spectrum

Toxicity Profile

Route of Exposure

Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.

Mechanism of Toxicity

Bromazepam binds to the GABA receptor GABA_A, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced.

Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound. Route of Elimination: Urine (69%), as metabolites Half Life: 10-20 hours

Toxicity Values

Not Available

Lethal Dose

Not Available

Carcinogenicity (IARC Classification)

No indication of carcinogenicity to humans (not listed by IARC).

Uses/Sources

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

Minimum Risk Level

Not Available

Health Effects

They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive.

Symptoms

Not Available

Treatment

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Concentrations

Not Available

External Links

DrugBank ID

DB01558

HMDB ID

HMDB0015511

FooDB ID

Not Available

Phenol Explorer ID

Not Available

KNApSAcK ID